Zydus completes acquisition of Sterling Biotech fermentation-based API business
Zydus Lifesciences has completed its acquisition of Sterling Biotech's fermentation-based active pharmaceutical ingredients business, expanding its manufacturing capabilities in India.
The transaction, completed on 2 November 2026 under a business transfer agreement originally signed in September 2024, includes a manufacturing facility near Vadodara and API operations associated with products such as lovastatin, daunorubicin, doxorubicin and epirubicin.
The original agreement specified consideration of ₹84 crore subject to closing adjustments, although the final adjusted transaction amount was not reliably confirmed in the supplied reporting, making the completion and manufacturing expansion the principal verified developments.
Field | Content |
Article Type | Deals |
Acquirer | Zydus Lifesciences |
Seller | Sterling Biotech |
Deal Type | Active pharmaceutical ingredients business acquisition |
Transaction Status | Completed |
Completion Date | 2 November 2026 |
Original Agreement Date | 17 September 2024 |
Transaction Structure | Business transfer agreement |
Acquired Business | Fermentation-based active pharmaceutical ingredients operations |
Manufacturing Facility | Facility near Vadodara, India |
Manufacturing Technology | Fermentation-based API production |
Example API | Lovastatin |
Oncology API Examples | Daunorubicin; doxorubicin; epirubicin |
Therapeutic Areas | Cardiovascular medicine; oncology |
Original Agreement Consideration | ₹84 crore subject to closing adjustments |
Final Adjusted Consideration | Not reliably confirmed in supplied summary |
Geographic Scope | India |
Regulatory Status | Business acquisition completion; no new drug marketing approval announced |
What Happened | Zydus Lifesciences completed its acquisition of Sterling Biotech's fermentation-based API business under a previously signed business transfer agreement. |
Why It Matters | The acquisition adds fermentation-based API manufacturing capacity and capabilities relevant to established pharmaceutical ingredients, including oncology medicines. |
Strategic Rationale | Expand Zydus' manufacturing infrastructure and strengthen its position in specialised active pharmaceutical ingredients. |
Transaction History | Agreement signed in September 2024 and acquisition completed in November 2026. |
Financial Clarification | The original agreement cited ₹84 crore subject to adjustments; no revised final consideration is asserted. |
Key Takeaway | Zydus has completed a strategic API manufacturing acquisition, adding fermentation capabilities and a facility near Vadodara. |
What to Watch | Facility integration, production capacity, manufacturing investment, regulatory compliance and future API supply expansion. |
Primary Source | Zydus Lifesciences corporate announcement via BazaarWatch |
Primary Source URL | https://bazaarwatch.com/announcement/270004/zydus-lifesciences-limited-general-updates |
Relevant Date | 2 November 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Commentaires